SCHEMBL4058065

SCHEMBL4058065

CS(=O)(=O)Nc1cccc(-c2nc3ccc(-c4ccco4)cc3o2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 6/20 0.54
MAPT P10636 7/20 0.46
LMNA P02545 6/20 0.46
POLB P06746 2/20 0.46
HPGD P15428 2/20 0.46
MEN1 O00255 1/20 0.46
HTT P42858 1/20 0.46
KMT2A Q03164 1/20 0.46
RCE1 Q9Y256 1/20 0.46
NPC1 O15118 3/20 0.44
RAB9A P51151 3/20 0.44
CYP1A2 P05177 4/20 0.44
CYP3A4 P08684 4/20 0.44
USP2 O75604 3/20 0.44
CYP2D6 P10635 3/20 0.44
CYP2C19 P33261 3/20 0.44
CYP2C9 P11712 1/20 0.44
TSHR P16473 1/20 0.44
MAPK1 P28482 1/20 0.44
HIF1A Q16665 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4063786 0.83 CASP3 (0.61) TP53MAPTLMNAPOLBHPGD
SCHEMBL4055533 0.81 TP53 (0.57) TP53MAPTLMNAPOLBHPGD
SCHEMBL4052767 0.80 VSIR (0.56) TP53MAPTLMNAPOLBHPGD
SCHEMBL4051830 0.79 RAB9A (0.55) TP53MAPTPOLBHPGDMEN1
SCHEMBL4056863 0.79 NPC1 (0.55) TP53MAPTLMNAPOLBHPGD
SCHEMBL4052971 0.78 LCLAT1 (0.66) TP53MAPTLMNAPOLBHPGD
SCHEMBL4061714 0.78 ALOX5 (0.56) MAPTHPGDMEN1KMT2ANPC1
SCHEMBL4059615 0.78 RAB9A (0.60) TP53MAPTLMNAPOLBHPGD
SCHEMBL4051901 0.77 NPC1 (0.62) TP53MAPTHPGDMEN1KMT2A
SCHEMBL4059581 0.77 VSIR (0.54) MAPTHPGDNPC1RAB9ACLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B TP53 842/4885MAPT 4026/4885LMNA 2175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.